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Abstract
Elucidating virus-host interactions responsible for HIV-1 transmission is important for advancing HIV-1 prevention strategies.
To this end, single genome amplification (SGA) and sequencing of HIV-1 within the context of a model of random virus
evolution has made possible for the first time an unambiguous identification of transmitted/founder viruses and a precise
estimation of their numbers. Here, we applied this approach to HIV-1 env analyses in a cohort of acutely infected men who
have sex with men (MSM) and found that a high proportion (10 of 28; 36%) had been productively infected by more than
one virus. In subjects with multivariant transmission, the minimum number of transmitted viruses ranged from 2 to 10 with
viral recombination leading to rapid and extensive genetic shuffling among virus lineages. A combined analysis of these
results, together with recently published findings based on identical SGA methods in largely heterosexual (HSX) cohorts,
revealed a significantly higher frequency of multivariant transmission in MSM than in HSX [19 of 50 subjects (38%) versus 34
of 175 subjects (19%); Fisher’s exact p=0.008]. To further evaluate the SGA strategy for identifying transmitted/founder
viruses, we analyzed 239 overlapping 59 and 39 half genome or env-only sequences from plasma viral RNA (vRNA) and blood
mononuclear cell DNA in an MSM subject who had a particularly well-documented virus exposure history 3–6 days before
symptom onset and 14–17 days before peak plasma viremia (47,600,000 vRNA molecules/ml). All 239 sequences coalesced
to a single transmitted/founder virus genome in a time frame consistent with the clinical history, and a molecular clone of
this genome encoded replication competent virus in accord with model predictions. Higher multiplicity of HIV-1 infection in
MSM compared with HSX is consistent with the demonstrably higher epidemiological risk of virus acquisition in MSM and
could indicate a greater challenge for HIV-1 vaccines than previously recognized.
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Introduction
An effective sterilizing HIV-1 vaccine ideally should target virus
in the earliest stages of transmission, prior to dissemination and
establishment of persistent infection [1,2,3,4]. To be broadly
protective, such a vaccine must defend against a genetically diverse
set of viruses transmitted by different sexual practices and risk
behaviors. Results from the recently reported ‘Thai Trial’ RV144
of an experimental HIV-1 vaccine showed a decrease in virus
acquisition of 31.2% (p=0.04) based on a modified intention-to-
treat analysis and a trend for greater vaccine effectiveness in those
subjects identified as practicing lower risk behaviors [5]. These
findings suggest that an HIV-1 vaccine might be more efficacious
in preventing infection by some exposure routes than others
[5,6,7].
Recently, we and others employed SGA, direct sequencing, and
a model of random virus evolution to identify those viruses
responsible for transmission and productive clinical infection in
several largely heterosexual cohorts with acute HIV-1 subtype A,
B or C infection [8,9,10,11,12] and in Indian rhesus macaques
PLoS Pathogens | www.plospathogens.org 1 May 2010 | Volume 6 | Issue 5 | e1000890inoculated intra-rectally with SIVmac251 or SIVsmmE660 [13].
This experimental approach allows for the distinction of
transmitted/founder viruses that differ by as little as a single
nucleotide [10,13]. SGA-direct sequencing also makes possible the
identification of transmitted viral sequences in linked transmis-
sions, thereby enabling the unambiguous tracking of viruses from
donor to recipient across mucosal surfaces [9,13], and the
molecular cloning and analysis of those viruses actually responsible
for productive clinical infection [12].
Previous studies based on different experimental approaches
have been informative with respect to determining the overall
extent of viral diversity present in acute and early infection as a
surrogate for identifying and quantifying transmitted viruses
[14,15,16,17,18,19,20,21,22,23,24]. Such studies generally de-
scribed new infections as being either ‘‘homogeneous,’’ presum-
ably reflecting infection by one or few viruses, or ‘‘heterogeneous,’’
suggesting infection by more viruses. Based on these studies, a
substantial bottleneck in virus transmission was recognized to exist,
since the genetic complexity of viral quasispecies in the blood of
chronically infected individuals was generally much greater than
that in acutely infected subjects. Evidence for a bottleneck in virus
transmission, although not necessarily at the mucosal interface,
was further suggested by the longstanding observation that most
new infections are caused by R5 tropic viruses and not by X4
tropic viruses, which are common in chronic infection [25,26,27].
These studies and others in the related Indian rhesus macaque-
SIV infection model [13,28,29,30,31] thus focused attention on
the mucosa and submucosa as a potentially important barrier to
HIV-1 transmission and a site where critical early virus-host cell
interactions leading to transmission and productive clinical
infection likely take place [1,2,3,4,25,26,32]. However, it was
not until the application of SGA, direct amplicon sequencing, and
a model of random virus evolution to the analysis of viral genomes
in the acute infection period that actual transmitted/founder
viruses could be identified and their numbers precisely estimated
[10,13]. In the present study, we have applied this strategy to a
systematic analysis and comparison of multiplicity of HIV-1
infection in men who have sex with men (MSM) versus
heterosexuals (HSX).
Results
Study Subjects
SGA-direct sequencing was used to identify and enumerate
transmitted/founder env sequences in 28 acutely infected MSM
subjects who reported homosexual exposure as their primary HIV-
1 risk behavior and who denied injection drug use (IDU)
(Table 1). At the time of study, 14 subjects were HIV-1 ELISA
negative/western immunoblot (WB) negative (Fiebig stage II), 2
were ELISA+/WB2 (Fiebig stage III), 6 were ELISA+/WB
indeterminate (Fiebig stage IV) and 6 were ELISA+/WB+/p312
(Fiebig stage V) [10,33]. Subjects were identified based on clinical
symptoms of an acute retroviral syndrome, routine HIV testing in
a health care setting, or contact tracing of an HIV-1 infected index
case. Clinical histories of sexually transmitted diseases were not
available. Envelope sequences from chronically infected sexual
partners of two acutely infected subjects were also evaluated.
HIV-1 Env Diversity Analysis
A total of 1307 full-length env genes encoding gp160 were
sequenced from plasma vRNA (median of 40 sequences per
subject; range 23–89). In a composite neighbor-joining (NJ)
phylogenetic tree (Fig. 1), viral sequences formed distinct
patient-specific monophyletic lineages, each with high statistical
support. Sequences from known sexual partners, including two
acute-to-acute (AD77 to AD75 and AD83 to 04013240) and two
chronic-to-acute (LACU9000 to HOBR0961 and AD18 to AD17)
transmission pairs, also clustered significantly together (Fig. 1). All
sequences were HIV-1 subtype B. Among the 28 acutely infected
subjects, maximum within-patient env diversities ranged from
0.12% to 6.82% (Table 2). Sequences from 22 of these individuals
had distinctly lower env diversities (,0.75%) compared with env
diversities from six others (.1.25%). The latter diversity is
inconsistent with single virus transmission within the time frame
of acute and early infection (Fiebig stage I–V) [8,9,10,34], while
env diversity ,0.75% is consistent either with single variant
transmission or with transmission of two or more closely related
viruses. Phylogenetic and Highlighter analyses of env sequences
distinguished between these possibilities for each subject (Fig. 2;
see also www.hiv.lanl.gov/content/sequence/HIV/USER_
ALIGNMENTS/Li). Fig. 2A shows sequences from a subject
(04013440) who was infected by a single virus, Fig. 2B a subject
(04013211) infected by two viruses differing by only 4 nucleotides
out of 2619 (0.15%), Fig. 2C a subject (04013383) infected by two
viruses differing by 65 of 2547 nucleotides (2.55%), and Fig. 2D a
subject (04013448) infected by four viruses differing by as many as
47 of 2655 nucleotides (1.79%) with additional sequences showing
recombination between the transmitted/founder lineages. Alto-
gether, we determined that 10 of 28 subjects (36%) had been
productively infected by more than one virus (Table 2).
Model Analysis of HIV-1 Diversification
We next analyzed the env sequences using a mathematical model of
random virus evolution that we previously described [10,13,34].
Sequences resulting from multivariant transmission, APOBEC
hypermutation, early stochastic mutation, selection by cytotoxic T-
cells, or recombination violate model predictions (Table 2) [10,34].
Once these confounders were accounted for, lineage-specific env
sequences from each subject conformed to model predictions and
coalesced to most recent common ancestor sequences at or near the
time of virus transmission estimated from clinical histories and
laboratory staging. These results thus corroborated a large body of
evidence supporting the SGA-direct sequencing strategy for
identifying transmitted/founder viruses [8,9,10,11,12,13,35]. As an
Author Summary
Understanding the biology of sexual transmission of HIV-1
could contribute importantly to the development of
effective prevention measures. However, different routes
of virus transmission (vaginal, rectal, penile or oral) and
inaccessibility of tissues at or near the time of virus
transmission make this goal elusive. Here, we apply single
genome amplification and sequencing of plasma HIV-1
and a model of random virus evolution to a cohort of
acutely infected men who have sex with men (MSM) and
find that MSM are twice as likely as heterosexuals to
become infected by multiple viruses as opposed to a
single virus. Some MSM subjects were infected by as many
as 7 to 10 or more genetically distinct viruses as a
consequence of a single exposure event. We go on to
molecularly clone the first full-length transmitted/founder
subtype B HIV-1 virus and show that it is highly replicative
in human CD4+ T-cells but not macrophages. Our study
provides the first comparative, quantitative analysis of the
multiplicity of HIV-1 infection in the two primary risk
groups—MSM and heterosexuals—driving the global
pandemic, and we discuss the implications of the findings
to HIV-1 vaccine development and prevention research.
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whose history of virus exposure was particularly well-documented
(Table 1 and Fig. 3), if plasma vRNA and PBMC viral DNA
(vDNA) sequences spanning the complete (9.2 Kb) viral genome
coalesced to the same viral sequence as didenv-onlysequences and if a
molecular clone of this viral genome encoded replication competent
virus, as would be expected for an authentic transmitted/founder
virus. For this analysis, we used SGA-direct sequencing to determine
env-only sequences (n=51) and overlapping 59(n=92) and 39(n=96)
half genome sequences (Fig. 4). All 239 vRNA and vDNA sequences
coalesced to a single transmitted/founder genome in a time frame
consistent with the clinical history of virus exposure as recently as 11
days earlier. The estimated time to a most recent common ancestor
(MRCA) sequence for env-only sequences was 8 days (95% CI 5–11)
and for all sequences 6–11 days (CI 3–14). MRCA estimates are
frequently lower than clinical estimates [10] or experimentally
determined intervals between transmission and virus sampling in the
rhesus macaque-SIV infection model [13] because of purifying
selectionorvarianceinestimatedparametersofvirusreplication[34].
The inferred transmitted/founder viral genome in subject AD17
contained intact LTR-gag-pol-vif-vpr-tat-rev-vpu-env-nef-LTR elements,
a finding we have replicated for transmitted/founder viruses from 38
other subjects infected by HIV-1 subtypes A, B, C or D ([12] and
H.L. and G.M.S., unpublished). A proviral clone (pAD17.1) of the
transmitted/founder viral genome from subject AD17 (Fig. 5A),
when transfected into 293T cells, produced virions that were
infectious and highly replicative in human CD4+ T-cells, but
interestingly, not in monocyte-derived macrophages from the same
normal donors (Fig. 5B). pAD17.1 virus was CCR5 tropic in
JC53BL-13 cells (Fig. 5C) and in GHOST(3) cells [36], where it
infected cells bearing CD4 and CCR5 but not CD4 and CXCR4
(G.M.S., unpublished).
High Multiplicity Infection Followed by Recombination
Extremes in HIV-1 diversity in acute infection could be
informative regarding biological events underlying virus transmis-
sion. Subject 04013171 had the greatest env diversity (6.82%)
(Table 2). This subject admitted to unprotected receptive anal
intercourse with multiple partners over a single eight hour period
four weeks before the onset of flu-like symptoms, consistent with
his Fiebig IV staging. Fig. 6 shows a NJ tree and Highlighter plot of
86 plasma derived env sequences, which revealed 10 unique
Table 1. Demographics, risk group and baseline laboratory data.
Subject Subtype
Geographic
location
Sexual
partners Sample date
Viral load
RNA/ml
CD4 count
cells/ml ELISA
a
Western
blot
Fiebig
stage
04013171 B New York Multiple 2/6/02 3,700,000 213 R indet 4
04013211 B New York Multiple 8/23/02 19,900,000 846 R neg 3
04013226 B New York Single 11/20/02 26,700,000 175 N neg 2
04013240 B New York Multiple 1/21/03 2,240,000 297 N neg 2
04013242 B New York Multiple 1/23/03 5,790,000 251 R indet 4
04013291 B New York Multiple 6/4/03 1,490,000 179 R pos(p31-) 5
04013296 B New York Multiple 8/5/03 8,050,000 395 N neg 2
04013321 B New York Single 10/10/03 6,250,000 407 N neg 2
04013327 B New York Single 1/27/04 8,720,000 248 R indet 4
04013383 B New York Multiple 4/5/05 584,000 531 N neg 2
04013396 B New York Multiple 8/16/05 1,600,000 581 R indet 4
04013419 B New York Multiple 3/14/06 21,200,000 226 N neg 2
04013440 B New York Multiple 10/17/06 .100,000 205 N neg 2
04013446 B New York Single 11/28/06 .100,000 438 R neg 3
04013448 B New York Single 1/19/07 28,600,000 536 N neg 2
AD17 B New York Multiple 6/14/99 47,600,000 nos N neg 2
AD75 B New York Multiple 11/6/02 21,400,000 nos N neg 2
AD77 B New York Multiple 11/15/02 130,000 nos R pos(p31-) 5
AD83 B New York Multiple 1/22/03 448,000 nos R pos(p31-) 5
HOBR0961 B Alabama Single 10/31/91 599,238 794 N neg 2
INME0632 B Alabama Single 8/9/90 2,217,670 739 N neg 2
701010055 B North Carolina nos
b 10/5/06 31,513,812 432 N neg 2
701010068 B North Carolina Multiple 10/24/06 3,714,386 109 R indet 4
700010106 B North Carolina nos 10/19/06 84,545,454 277 N neg 2
701010027 B North Carolina nos 8/29/06 194,744 542 R pos(p31-) 5
701010108 B North Carolina nos 6/28/07 14,711 592 R pos(p31-) 5
700010246 B North Carolina nos 6/7/07 4,395,721 1012 R indet 4
700010238 B North Carolina nos 5/8/07 596,908 587 R pos(p31-) 5
aR - reactive; N - nonreactive.
bnos - not otherwise specified.
doi:10.1371/journal.ppat.1000890.t001
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PLoS Pathogens | www.plospathogens.org 3 May 2010 | Volume 6 | Issue 5 | e1000890transmitted/founder virus lineages. In addition, 20 inter-lineage
recombinants were identified based on shared polymorphisms in
the Highlighter plot with corroboration by Recco analysis [37].
Among these recombinant sequences, the Hudson-Kaplan test
[38] indicated a minimum of 44 recombination breakpoints.
Interestingly, sequences corresponding to 4 of the 10 virus lineages
in subject 04013171 were sampled only once. We could be
confident that these represented unique transmitted/founder
viruses and not recombinants between two or more predominant
virus lineages because of the large number of unique nucleotide
changes in each sequence that far exceeded the diversity observed
empirically [8,9,10,13] or estimated to occur based on mathe-
Figure 1. Neighbor-joining (NJ) tree of full-length HIV-1 gp160 env sequences from 28 acutely infected subjects and 2 chronically
infected sexual partners. Two chronic-to-acute (LACU9000 to HOBR0961 and AD18 to AD17) and two acute-to-acute (AD77 to AD75 and AD83 to
04013240) transmissions were documented, with donor sequences shown in blue and recipient sequences shown in green. Individual sequences with
APOBEC G-to-A hypermutation were excluded from the analysis. Bootstrap values ($70%) are shown for intra-subject clusters, partner pairs, and
additional sequences with evidence of epidemiologic linkage. The horizontal scale bar represents 1.0% genetic distance.
doi:10.1371/journal.ppat.1000890.g001
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the end of Fiebig stage IV) [10]. Power calculations further
indicated that with a sample size of 86 sequences, there is a .95%
probability of detecting minor sequences representing at least 4%
of the population (see Methods). These findings suggest that more
extensive sampling might result in the detection of an even greater
number of transmitted/founder viruses in this individual. Subject
701010068 had the second highest env diversity (4.43%) among the
study subjects (Table 2). He reported a single high risk exposure
event involving unprotected receptive anal intercourse with two
individuals, one HIV negative and the other HIV positive. He
developed flu-like symptoms approximately two weeks later and
was studied three weeks after that, again at Fiebig stage IV. Based
on the earlier analysis of subject 04013171 (Fig. 6), we were
concerned that viral recombination [39,40,41,42], which is
sequence length and time (from infection) dependent [10,13,40],
could confound the identification of discrete transmitted/founder
virus lineages. This could be especially problematic in subjects
infected with many different transmitted/founder viruses as
opposed to two, since in the former case it is far more likely that
doubly or multiply infected cells will spawn heterozygous virus
progeny that lead in the next virus generation to recombinant viral
genomes [39,40,41]. To test this hypothesis, we amplified and
sequenced seventy-two 39 half genome segments of plasma vRNA
from subject 701010068 and then analyzed env gp41 (1035 bp), env
gp160 (2630 bp), and 39 half genome regions (4734 bp) separately.
The gp41 sequences (Fig. 7A) revealed discrete low diversity
lineages comprised of identical or nearly identical sequences. We
interpreted 7 of these sequence clusters as likely to have arisen
from distinct transmitted viruses and the remaining sequences to
represent inter-lineage recombinants. Clusters of identical or
nearly identical sequences were also evident in gp160 sequences
(Fig. 7B), but with less clarity due to additional inter-lineage
recombination events in the longer sequences. For example,
sequences corresponding to lineage 4 in the gp41 sequences
(depicted in light blue in Fig. 7A) were dispersed into five widely
separated branches in the gp160 tree due entirely to recombina-
tion (Fig. 3B). Similarly, sequences comprising lineage 6 in the
gp41 sequences (depicted in red in Fig. 7A) were dispersed into
three widely separated branches in the gp160 tree, again due
entirely to recombination (Fig. 7B). These findings were
supported by Hudson-Kaplan analysis [38], which indicated a
minimum of 27 recombination breakpoints among the gp160 env
sequences. Interspersion of sequences was even more dramatic in
the 39 half genome tree (Fig. 7C). Remarkably, of the 72 39 half
genome sequences depicted in Fig. 7C, 63 (88%) represented
overt recombinants between two or more transmitted/founder
lineages demonstrable by visual inspection and by computer-
assisted algorithms. Only two (dark blue) sequences labeled L7 and
L9 at the very top of the tree (Fig. 7C), three (green) sequences
labeled B1, L1 and P7 in the middle of the tree, and four (gray)
sequences labeled B27, E1, A2 and J1 at the very bottom of the
tree showed no evidence of recombination. These findings,
together with corroborating data from env-only sequences
[8,10,11], lead to the surprising conclusion that by the time of
first antibody detection in acute HIV-1 infection (Fiebig stages
III/IV), a majority of circulating viruses may be recombinants.
This finding is testament to the large number of doubly (or
multiply) infected cells in acute and early infection and further
evidence of the rapidity with which virus diversifies [43,44],
making clear that in order to identify non-recombinant transmit-
ted/founder HIV-1 (or SIV) genomes [10,12,13], it is necessary to
characterize viral sequences as close to the transmission event as
possible.
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versus Heterosexuals
Four studies, including the present one, have estimated the
numbers of viruses responsible for transmission and productive
HIV-1 infection after heterosexual or homosexual exposure using
identical SGA-direct env amplicon sequencing methods [8,9,10].
One of these evaluated the frequency of multivariant transmission
in a cohort of cohabitating HIV-1 discordant (antiretroviral naı ¨ve)
heterosexual couples in Zambia and Rwanda followed prospec-
tively for HIV-1 transmission [9]. Remarkably, only 2 of 20 [10%;
95% confidence interval (CI) 1–32%] of the epidemiologically
linked infections resulted from multivariant transmission, a finding
attributed to the chronicity of infection in the virus positive
partner, lower prevalence of comorbid conditions such as
untreated tuberculosis or sexually transmitted infections, and the
heterosexual route of transmission. Since the frequency of
multivariant transmission in HSX in that study was substantially
less than what we observed for MSM [2 of 20 HSX (10%, CI 1–
32%) versus 10 of 28 MSM (36%, CI 19–56%); Fisher’s exact
p=0.042, odds ratio 4.85, 95% CI 1.1 - inf], we performed a
combined analysis of data from all four studies, which included
225 patients infected by HIV-1 subtypes A, B or C (Table 3).
Again we found that the proportion of MSM subjects infected by
more than one virus was substantially higher than for HSX [19 of
50 (38%) versus 34 of 175 (19%); Fisher’s exact p=0.008, odds
ratio 2.5, 95% CI 1.2–5.3]. The MSM subjects were all infected
with HIV-1 subtype B; a comparison to only the subset of HSX
infections that were subtype B was still significant (Fisher’s exact
p=0.01, odds ratio 2.9, 95% CI 1.2–7.1). The frequency of
multiple infections in HSX was not statistically different among
subtypes A, B and C nor was it different between males and
females. Differences in the frequency of multivariant HIV-1
transmission in MSM versus HSX could not be accounted for by
the numbers of sequences analyzed per subject nor by the clinical
stage of subjects at the time of study. In the study by Haaland [9],
the median number of sequences analyzed was 40, in Keele [10] it
was 25, and in Abraham [8] it was 22. In the present study, the
median number of sequences that we determined as part of our
initial survey was 33 (Table 2). We used this lower number of
sequences for statistical comparisons of single and multivariant
transmissions in MSM versus HSX subjects in order to allow for
comparability among the four studies. When, in this initial
Figure 2. NJ trees and Highlighter plots of HIV-1 env diversity. Full-length gp160 env sequences from four subjects are depicted by NJ tree
phylogenies and by Highlighter, a sequence visualization tool that allows tracing of common ancestry between sequences based on individual
nucleotide polymorphisms [10]. Sequences from subject 04013440 (A) showed productive infection by a single virus, from subject 04013211 (B)
infection by two closely related viruses, from subject 04013383 (C) infection by two distantly related viruses, and from subject 04013448 (D) infection
by four viruses with inter-lineage recombinants denoted by orange symbols in the NJ tree. The horizontal scale bar represents genetic distance.
doi:10.1371/journal.ppat.1000890.g002
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PLoS Pathogens | www.plospathogens.org 7 May 2010 | Volume 6 | Issue 5 | e1000890sequence set, we identified samples containing more than one
transmitted/founder virus lineage, we went on to obtain additional
sequences (as many as 89) in order to estimate more precisely the
numbers of transmitted/founder viruses (Table 2). Increasing the
numbers of sequences analyzed allowed for greater accuracy and
precision in estimating the numbers of viruses transmitted in those
individuals with many transmitted viruses (e.g., subjects 04013448,
04013171 and 701010068 in Figs. 2D, 6 and 7), but it did not
affect the discrimination between those subjects infected by one
virus versus those infected by more than one virus. Finally, we
found no significant correlation between the clinical stage of
subjects at the time of plasma sampling and the numbers of
transmitted/founder viruses identified in those samples: among the
four studies, there was a total of 95 antibody negative subjects
(Fiebig stages I–II) and 130 antibody positive subjects (Fiebig
stages III–VI). Twenty subjects (21%) in the former group and 33
subjects (25%) in the latter group had evidence of productive
infection by more than one virus, which was not significantly
different (odds ratio 1.27; 95% CI 0.65–2.54; Fisher’s exact
p=0.53).
Discussion
Previous studies used less precise methods for estimating
multiplicity of HIV-1 infection in HSX and MSM subjects and
reported widely varying results with a trend for higher multiplic-
ities in MSM [15,16,17,18,19,20,21,22,24]. We report here new
SGA-based determinations that show significant differences in the
multiplicity of virus infection between the two risk groups: MSM
were twice as likely as HSX subjects to become infected by more
than one virus, with some MSM acquiring as many as 7 to 10 or
more viruses. These findings are consistent with the higher
epidemiological risk of HIV-1 acquisition in MSM compared with
HSX and may be explained in part by the anatomical and
immunohistological differences between the male and female
genitourinary tracts and the lower intestine.
A limitation of the current study is that it represents a retrospective
comparison of multivariant HIV-1 transmission among patient
cohorts having different enrollment criteria and different behavioral
risk assessments. It must be noted, however, that all study subjects
from all cohorts were queried extensively with regard to potential
HIV-1 infection risk behaviors. This included acutely infected
subjects identified by cross-sectional screening methods [45], subjects
enrolled prospectively into HIV-1 discordant couple [9] or Acute
Infection Early Disease Research Program cohorts [46], and source
plasma donors who became HIV-1 infected during a period of serial
plasma collections [10]. The latter subjects, whom we studied
anonymously, underwent exhaustive pre-enrollment interrogation for
HIV and IDU risk behaviors according to a standardized FDA-
approved protocol (http://www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/Blood/
ucm073445.htm) that included a written questionnaire and
interview inquiring about MSM and IDU activities, sex-for-money,
sex with a partner who had sex-for-money, or sexwith an individual
known to be HIV positive. Source plasma donors also underwent
serial laboratory testing for surrogate laboratory markers that could
indicate injection drug use (e.g., liver transaminase elevations and
hepatitis B or C nucleic acids or antibodies), and these markers were
negative among qualified donors. Nonetheless, self-reporting of risk
behaviors among paid plasma donors is imperfect [47], and it is
possiblethatsome subjectswhomwecategorized asbelongingtothe
HSX risk group actually had additional risks such as IDU or MSM.
However, even if this were the case, it would likely bias the findings
in the HSX group toward a greater (not lesser) number of
transmitted viruses [48]. Not surprisingly, when we excluded all
source plasma donor subjects from our comparative analysis of
multivariant HIV-1 transmission, the difference between MSM and
HSX groups was still statistically significant [19 of 50 (38%) versus
25 of 119 (21%), respectively; Fisher’s exact p=0.03, odds ratio 2.3,
95% CI 1.04–5.02]. We conclude that within the limitations of self-
reporting and surrogate marker testing, study subjects in the cohorts
we examined were correctly assigned to HSX and MSM risk
groups, differences in multiplicity of virus transmission between the
two groups were significant, and overall study findings were unlikely
to have been confounded by injection drug use. Future studies can
Figure 3. Time course of HIV-1 exposure, symptom onset, viral kinetics, and initiation of antiretroviral therapy in subject AD17. ARS,
acute retroviral syndrome. HAART, highly active antiretroviral therapy. For purposes of mathematical modeling, a plasma virus load of 10 RNA
molecules per milliliter was estimated at day 6.
doi:10.1371/journal.ppat.1000890.g003
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PLoS Pathogens | www.plospathogens.org 9 May 2010 | Volume 6 | Issue 5 | e1000890benefit from a prospective trial design and a common behavioral
and medical questionnaire [49,50].
It is noteworthy that while multivariant HIV-1 transmission was
twice as common in MSM than in HSX, still more than half of
MSM subjects showed evidence of productive infection by just one
virus. Moreover, the adjusted median (calculated from subjects
with multivariant transmissions only) was 3 in MSM compared
with 2 in HSX (Table 3). Even in the Fiebig II subject AD17,
where we analyzed a total of 239 sequences (giving us a 95%
probability of detecting a second transmitted/founder virus
lineage at 1.25% prevalence), all of the sequences coalesced
phylogenetically to a single virus, thus providing no evidence for
transmission of more than one virus. Elsewhere, we have used 454
deep sequencing to analyze tens of thousands of sequences from
three additional Fiebig stage II MSM subjects in whom SGA-
direct sequencing suggested transmission and productive clinical
infection by a single virus (Will Fischer, B.F.K., G.M.S. B.T.K.,
unpublished). Even with this greatly enhanced sensitivity of
detection of minor sequences, we found no evidence of
transmission by more than one virus in these subjects. Considered
together, the findings of the present study, previously published
studies [8,9,10], and work in progress (Will Fischer, B.F.K.,
G.M.S., B.T.K), all suggest that a substantial proportion of HSX
and MSM patients acquire HIV-1 infection as a consequence of
transmission and productive infection by literally one virion or one
infected cell. The implication of this finding is that in order for a
vaccine, microbicide or other prevention modality to be protective
in this fraction of individuals, it need only prevent infection by a
single virus or infected cell. Conversely, there is another subset of
HSX and MSM subjects in whom the multiplicity of infection is
higher. Since the proportion of such multiply infected individuals
is far higher than would be expected from a Poisson distribution of
independent, low frequency events (see Abrahams [8] for
discussion), we suspect that biological events underlying virus
Figure 4. NJ trees and Highlighter plots of HIV-1 diversity in 59 and 39 half genomes in subject AD17. Sequences in (A) and (B) were
derived from overlapping 59 and 39 SGA amplicons spanning the complete viral genome. Blue symbols represent sequences from day 14 and green
symbols day 17 as depicted in Fig. 3. Solid ovals represent sequences derived from plasma vRNA and solid triangles represent sequences derived
from peripheral blood mononuclear cell DNA.
doi:10.1371/journal.ppat.1000890.g004
Figure 5. Molecular cloning and biological analysis of the transmitted/founder virus from subject AD17. (A) Cloning strategy and
genome organization of the transmitted/founder HIV-1 provirus pAD17.1. (B) Replication of pAD17.1 virus in activated primary human CD4+
lymphocytes (left panel) and monocyte-derived macrophages (right panel) from the same normal blood donor. Results were replicated three times in
cells from different donors, each time showing efficient replication of pAD17.1 virus in CD4+ T cells but not in macrophages. (C) pAD17.1 virus
infection of JC53BL-13 cells assessed by luciferase expression [12] in the absence or presence of the CXCR4 inhibitor AMD3100 (1.2 uM) or the CCR5
inhibitor TAK779 (10 uM) or both. Results from four experiments are expressed as infectivity (mean 61 S.D.) relative to control wells lacking
coreceptor inhibitor: NL4.3 is X4 tropic, YU2 is R5 tropic, WEAU1.60 is dual R5/X4 tropic, and pAD17.1 is R5 tropic.
doi:10.1371/journal.ppat.1000890.g005
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single virus are different and that challenges faced by vaccines and
microbicides in the higher multiplicity infection group may be
higher.
Another interesting observation from the present study relates to
viral recombination. Although recombination was not a primary
study objective, the identification of two or more transmitted/
founder genomes in acutely infected subjects gave us a unique
opportunity to examine the dynamics and extent of recombination
in primary HIV-1 infection. Five features of our study distinguish
it from previous reports of HIV-1 recombination [39,40,41,42].
First, we studied subjects at very early clinical stages following
virus transmission (Fiebig stages II–V). Second, we used SGA-
direct amplicon sequencing, which provides for a proportional
representation of virus present in the plasma, including those that
are recombinant [11]. Third, SGA eliminates in vitro recombina-
tion artifacts resulting from Taq polymerase-mediated template
switching [11]. Fourth, SGA allowed us to identify the exact
nucleotide sequences of full-length transmitted/founder virus env
genes unambiguously and to distinguish these viruses and their
progeny from viruses that contained even short regions of
recombinant sequence. Fifth, SGA-direct sequencing of 39 half
genomes allowed us to examine recombination across the
boundaries of vif-vpr-tat-rev-vpu-env-nef-LTR. Figs 2D, 6 and 7
illustrate examples of recombination and Table 2 summarizes the
findings in all multiply infected subjects. Seven of 9 subjects had
evidence of recombination within gp160 env (one subject, AD77,
could not be analyzed because of excessive virus diversity at a late
Fiebig stage). The proportion of recombinants ranged from 0 of 30
sequences in subject 04013211 to 30 of 72 sequences (42%) in
subject 701010068. In the latter subject, we amplified a longer
fragment of the viral genome so as to include the 39 half; this
allowed us to compare recombination frequencies within gp41
(only), gp160 (only) or the full-length 39 half genome. The
proportion of recombinants in these three regions was 13/72
(18%), 30/72 (42%) and 63/72 (88%), respectively. Recombina-
tion breakpoints were more common in sequences flanking gp160
env than within env (Fig. 7C), a finding similar to that reported by
Simon-Loriere and colleagues for HIV-1 inter-subtype recombi-
nation [42]. In subject 701010068, where 88% of sequences
corresponding to only half the viral genome were recombinant, it
is likely that nearly all of the full-genome sequences at this time
Figure 6. NJ tree and Highlighter plot of HIV-1 env diversity in subject 04013171. Sequences emanating from ten transmitted/founder
viruses are color-coded and identified as variants 1–10. Inter-lineage recombinants are depicted in orange. The horizontal scale bar represents genetic
distance.
doi:10.1371/journal.ppat.1000890.g006
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infection event in which a cell is infected by two or more viruses,
our findings suggest that in acutely infected humans at or near
antibody seroconversion (Fiebig stages III/IV), a substantial
fraction of productively infected cells are infected by more than
one virus, a circumstance undoubtedly facilitated by initially high
virus loads at a time when target cell availability is rapidly
declining [51].
A final unique aspect to our study was its in-depth analysis of
early virus replication kinetics (Fig. 3) and diversification (Fig. 4)
in subject AD17 who was exposed to HIV-1 by receptive anal
intercourse approximately 6 days before developing symptoms of
the acute retroviral syndrome and 14–17 days before peak plasma
viremia of 47,600,000 RNA molecules/ml. This exposure to HIV-
1 was through a new sexual partner (AD18) whom we could prove
by phylogenetic analysis was the source of subject AD17’s acute
HIV-1 infection (Fig. 1). Assuming a plasma viral load (vL) of 10
RNA copies/ml at the time of symptom onset 6 days after virus
infection, then during the period between days 6 and 14, vL
increased by a factor of ,10
6. This implies virus grew
exponentially with growth rate r=1.73/day, i.e. exp(1.73*8)
,10
6. This expansion rate is slower than the expansion rate
calculated by Little [52] of 2.0/day but similar to that reported by
Stafford [53] of 1.67/day. Subject AD17 began HAART on day
17, and between days 17 and 25, vL fell approximately 200-fold.
Assuming HAART is nearly 100% effective [54], then the
productively infected cell death rate, d, can be calculated from
the rate of vL decline as ln(200)/8=0.66/day. These values can
then be used to estimate R0, the basic reproductive number, as (1+
r/d) exp(rt), where t is the intracellular delay phase. If we ignore
the delay phase, then R0=(1+ r/d) and the estimate of R0 is 3.6.
However, if we include the delay phase and assume t is one day,
then R0=20.4. This is larger than the estimates in Stafford [53].
These data support the basic assumptions used in the development
of our model of early HIV-1 evolution [10,34], and the genomic
integrity and replication competence of the full-length proviral
clone pAD17.1 provide further corroboration of the model. Only
four other transmitted/founder virus molecular clones have been
described ([12] and J.S.G. and G.M.S., unpublished), and all of
these correspond to HIV-1 subtype C viruses resulting from
heterosexual transmissions. With the addition of the pAD17.1
clone, we now have molecular proviral clones representing male-
to-male rectal transmission (pAD17.1), male-to-female vaginal
transmission (pZM246F-10; pZM247Fv1; pZM247Fv2), and
female-to-male penile transmission (pZM249M-1). All of these
viruses are R5 tropic, replicate efficiently in activated human
CD4+ T cells, but fail to replicate efficiently in monocyte-derived
macrophages. Such molecular clones of transmitted/founder
viruses should represent a rich resource for studying the biology
of HIV-1 transmission and its prevention.
In summary, the findings presented here provide for the first
time a comparative, quantitative view of the HIV-1 transmission
event in two patient risk groups that dominate the HIV-1
pandemic. In doing so, they highlight both challenges and
opportunities confronting candidate vaccines, microbicides, and
other prevention modalities. Elucidation of the biological basis of
single versus multivariant transmission in MSM and HSX could
help advance prevention strategies [55,56,57], with quantitative
analyses of transmitted/founder viruses representing a potentially
valuable new endpoint in vaccine and microbicide trial design and
assessment [5,6,49,50].
Materials and Methods
Study Subjects
This study was conducted according to the principles expressed
in the Declaration of Helsinki. It was approved by the Institutional
Review Boards of the University of Alabama at Birmingham,
Rockefeller University, Duke University, and the University of
North Carolina. All patients provided written informed consent for
the collection of samples and subsequent analysis. Blood samples
were obtained from 28 subjects with acute HIV-1 infection and
from chronically infected sexual partners of two of them. Blood
specimens were generally collected in acid citrate dextrose and
Figure 7. NJ trees and Highlighter plots of HIV-1 diversity in env gp41, env gp160 and 39 half genomes in subject 7010100068.
Seventy-two 39 half genomes were amplified and sequenced and segments of each are represented in panels A (env gp41), B (env gp160) and C (39
half genome). The progeny of transmitted/founder viruses are color-coded and identifiable as discrete ‘rakes’ of identical or nearly identical
sequences (variants 1–7) in the env gp41 segments shown in panel A. The relatedness of sequences emanating from the seven transmitted/founder
viruses is progressively obscured in panels B and C as longer segments are compared due to inter-lineage recombination. The horizontal scale bar
represents genetic distance.
doi:10.1371/journal.ppat.1000890.g007
Table 3. Multiplicity of HIV-1 infection in MSM vs heterosexual subjects.
Route of
transmission Study
Virus
subtype
Total
subjects
Single variant
transmission Multiple variant transmission Number of variants
n n % n % p value
odds
ratio median range
Adjusted
median
a
Heterosexual Keele [10] B 79 65 82.3% 14 17.7% 1 1–4 2
Abrahams [8] C 69 54 78.3% 15 21.7% 1 1–5 3
Haaland [9] A and C 27 22 81.5% 5 18.5% 1 1–6 2
Total 175 141 80.6% 34 19.4% 1 1–6 2
MSM Keele [10] B 22 13 59.1% 9 40.9% 1 1–6 3
Li (PLoS Path) B 28 18 64.3% 10 35.7% 1 1–10 3
Total 50 31 62.0% 19 38.0% 0.008 2.5 1 1–10 3
aAdjusted median values are for multivariant transmissions only.
doi:10.1371/journal.ppat.1000890.t003
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vapor phase liquid nitrogen.
Laboratory Staging
Plasma samples were tested for HIV-1 RNA, p24 antigen, and
viral specific antibodies by a battery of commercial tests. These
included quantitative Chiron bDNA 3.0 or Roche Amplicor vRNA
assays; Coulter or Roche p24 Ag assays; Genetic Systems Anti-HIV-
1/2 Plus O; and Genetic Systems HIV-1 WesternBlot Kit. Based on
these test results, subjects were staged according to the Fiebig
classification system for acute and early HIV-1 infection [33].
Viral RNA Extraction and cDNA Synthesis
For each sample, approximately 20,000 viral RNA copies were
extracted using the Qiagen BioRobot EZ1 Workstation with EZ1
Virus Mini Kit v2.0 (Qiagen, Valencia, CA). RNA was eluted in
60 ul of elution buffer and subjected to first strand cDNA synthesis
immediately by using the SuperScript III Reverse Transcriptase
according to manufacturer’s instructions (Invitrogen Life Tech-
nologies). Each first strand synthesis reaction included ,10,000 or
fewer vRNA molecules, 1X reverse transcription buffer, 0.5 mM
of each dNTP, 5 mM DTT, 2 units/ul of RnaseOUT, 10 units/ul
of SuperScript III reverse transcriptase and 0.25 uM of antisense
primer. The cDNA syntheses were performed using antisense
primers located at different genomic regions. The primers for
synthesizing the cDNA of env,5 9 half genome (U5, gag and pol) and
39 half genome (vif, vpr, tat, rev, vpu, env, nef, U3 and R) were env3out
59-TTGCTACTTGTGATTGCTCCATGT-39, 1.int.R1 59-CT-
TGCCACACAATCATCACCTGCCAT-39 and 1.R3.B3R 59-A-
CTACTTGAAGCACTCAAGGCAAGCTTTATTG-39, respec-
tively. The reactions were incubated at 50uC for 60 min, followed
by 55uC for an additional 60 min incubation. The reaction was
heat-inactivated at 70uC for 15 min, and then treated with
RNaseH at 37uC for 20 min. The synthesized cDNA was
subjected to 1
st round PCR immediately or stored frozen at
280uC.
Proviral DNA Extraction
Blood was collected from subject AD17 14–17 days following
exposure to HIV-1 at Fiebig stage II. Genomic DNA was
extracted from 1.3 million PBMCs using Qiagen Tissue DNA
Extraction kit according to manufacturer’s instructions.
Single Genome Amplification
cDNA or genomic DNA was serially diluted and distributed in
replicates of 8 PCR reactions in MicroAmp 96-well plates (Applied
Biosystems, Foster City, CA) so as to identify a dilution where
PCR positive wells constituted less than 30% of total number of
the reactions. At this dilution, most wells contain amplicons
derived from a single cDNA molecule. Additional PCR amplifi-
cations were performed using this dilution in 96-well reaction
plates. PCR amplification was carried out in presence of 1x High
Fidelity Platinum Taq PCR buffer, 2 mM MgSO4, 0.2 mM each
deoxynucleoside triphosphate, 0.2 uM each primer, and
0.025 units/ul of Platinum Taq High Fidelity polymerase in a
20-ul reaction (Invitrogen, Carlsbad, CA). The nested primers for
generating different genomic segments included: (1) full length env:
1
st round sense primer env5out 59-TAGAGCCCTGGAAG-
CATCCAGGAAG-39,1
st round antisense primer env3out 59-
TTGCTACTTGTGATTGCTCCATGT-39,2
nd round sense
primer env5in 59-TTAGGCATCTCCTATGGCAGGAAGA-
AG-39 and 2
nd round antisense primer env3in 59-GTCTCGA-
GATACTGCTCCCACCC-39; (2) 59 half genome: 1
st round
sense primer 1.U5.F1 59- CCTTGAGTGCTTCAAGTAG-
TGTGTGCCCGTCTGT-39,1
st round antisense primer 1.int.R1
59-CTTGCCACACAATCATCACCTGCCAT-39,2
nd round
sense primer 2.U5.F2 59-GTAGTGTGTGCCCGTCTGTT-
GTGTGACTC-39 and 2
nd round antisense primer 2.int.R2 59-
CAATCATCACCTGCCATCTGTTTTCCATA-39; (3) 39 half
genome: 1
st round sense primer 1.int.F1 59- ACAGCAGTA-
CAAATGGCAGTATT-39,1
st round antisense primer 1.R3.B3R
59- ACTACTTGAAGCACTCAAGGCAAGCTTTATTG-39,
2
nd round sense primer 2.int.F2 59-TGGAAAGGTGAAGGGG-
CAGTAGTAATAC-39 and 2
nd round antisense primer
2.R3.B6R 59- TGAAGCACTCAAGGCAAGCTTTATTGA-
GGC-39. PCR parameters were as follows: 94uC for 2 min,
followed by 35 cycles of 94uC for 15 s, 58uC for 30 s, and 68uC for
4 min (env) or 5 min (59 or 39 half genomes), followed by a final
extension of 68uC for 10 min. The product of the first-round PCR
was subsequently used as a template in the second-round PCR
under same conditions but with a total of 45 cycles. The amplicons
were inspected on precast 1% agarose E-gel 96 (Invitrogen Life
Technologies, Carlsbad, CA). All PCR procedures were carried
out under PCR clean room conditions using procedural safeguards
against sample contamination, including pre-aliquoting of all
reagents, use of dedicated equipment, and physical separation of
sample processing from pre- and post-PCR amplification steps.
DNA Sequencing
Amplicons were directly sequenced by cycle-sequencing using
BigDye Terminator chemistry and protocols recommended by the
manufacturer (Applied Biosystems, Foster City, CA). Sequencing
reaction products were analyzed with an ABI 3730xl genetic
analyzer (Applied Biosystems; Foster City, CA). Both DNA strands
were sequenced using partially overlapping fragments. Individual
sequence fragments for each amplicon were assembled and edited
using the Sequencher program 4.8 (Gene Codes; Ann Arbor, MI).
All chromatograms were inspected for sites of mixed bases (double
peaks), which would be evidence of priming from more than one
template or the introduction of PCR error in early cycles. Any
sequence with evidence of double peaks was excluded from further
analysis.
Sequence Alignments
All the sequence alignments were initially made with ClustalW and
then hand-checked using MacClade 4.08 to improve the alignments
according to the codon translation. Consensus sequences were
generated for each individual. The full sequence alignment is
available as a supplemental data file (www.hiv.lanl.gov/content/
sequence/HIV/USER_ALIGNMENTS/Li) and sequences are
deposited in GenBank (accession numbers: GU330247–GU331770).
Sequence Diversity Analysis
Complete env sequences (n=1307) were derived from 30
individuals, and 59 (U5, gag and pol)a n d3 9 (vif, vpu, tat, rev, env, nef,
U3, and R) halfgenomesequences (n=188)were derived fromPBMC
and plasma at two different time points from subject AD17. We
analyzed sequences for maximum sequence diversity and then
visually inspected each set of sequences using neighbor-joining (NJ)
and Highlighter tools (www.hiv.lanl.gov). Phylogenetic trees were
generated by the neighbor-joining method using ClustalW or PAUP.
Hypermutated Samples
Enrichment for APOBEC3G/F mutations violates the assump-
tion of constant mutation rate across positions as the editing
performed by these enzymes are base and context sensitive.
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assessed using Hypermut 2.0 (www.hiv.lanl.gov). Sequences that
yielded a p-value of 0.05 or lower were considered significantly
hypermutated and excluded from subsequent analyses.
Proviral DNA Cloning
To obtain an infectious molecular clone of the transmitted/
founder virus of subject AD17, we amplified overlapping 59 and 39
half genomes from proviral DNA of earliest sample (day 14; 6/11/
99) by single round PCR using Phusion Hot Start High-Fidelity
DNA polymerase (Biolabs). Both fragments contained a complete
LTR element and an overlap of 170 base pairs encompassing a
unique SalI restriction site. For the 59 half genome, U3-R-U5, gag,
pol, vif, vpr and tat1 was amplified. For the 39 half genome, tat1, rev1,
vpu, env, nef, tat2, rev2 and U3-R-U5 was amplified. The primers
were designed to complement exactly the confirmed transmitted/
founder sequence as determined by SGA-direct amplicon
sequencing. The recognition sequences of MluI and NotI restriction
enzymes were appended to the 59 ends of the sense and antisense
primers, respectively. Single round bulk PCR amplifications were
carried out in the presence of 1X Phusion Hot Start HiFi buffer,
0.2 mM of each deoxynucleoside triphosphate, 0.5 uM of each
primer, 3% final concentration of DMSO, and 0.02 units/ul of
Phusion Hot Start High Fidelity polymerase in 50 ul reactions.
The PCR product of each half genome was subjected to MluI and
NotI digestion and gel purification and then independently cloned
into the MluI-NotI site of TOPO XL vector (Invitrogen). The
ligation mixture was transformed into XL2 Blue MRF competent
cells and plated onto LB agar plates supplemented with 50 ug/ml
of kanamycin and grown overnight at 30uC. Single colonies were
selected and grown overnight in LB medium with same
concentration of kanamycin at 30uC with constant shaking.
Plasmid DNA was isolated and sequenced to confirm the identity
of transmitted/founder sequences. The 59 genome half was excised
and cloned into 39 TOPO XL vector by utilizing the MluI and SalI
restriction sites thereby generating the full length clone of the
transmitted/founder provirus.
Phenotypic Analyses
Replication competency of the full length molecular proviral
clone AD17.1 was assessed using 293T cells, JC53BL-13 cells
(NIH AIDS Research and Reference Reagent Program catalogue
#8129, TZM-bl), activated primary human CD4+ lymphocytes,
and monocyte-derived macrophages. Infectious virus stock
generation, Env-pseudotyped virus stocks, titrations, cell infections
and virus neutralization assays were performed according to
methods previously described [12]. Virus controls (replication
competent or Env-pseudotyped) included the HIV-1 macrophage-
tropic strains YU2 and BaL, the non-macrophage tropic T-cell
line-adapted strain NL4.3, the dual R5/X4 tropic strain
WEAU1.60, and the xenotropic MuLV env [12]. The coreceptor
inhibitors TAK779 and AMD3100 were obtained from the NIH
AIDS Research and Reference Reagent Program (4983 and 8128).
R5 and X4 tropism was assessed in both JC53BL-13 cells and in
GHOST(3) cells that stably express CD4 along with CCR5 or
CXCR4 or both or neither coreceptor.
Recombination Analyses
Recombination was evaluated using GARD [58] and Recco
[37] and by visual inspection of Highlighter plots. The minimum
number of recombination events required to explain sequence
datasets was estimated using the four-gamete method of Hudson
and Kaplan [38] as implemented in DNASP v5.00.07 [59].
Recombinant sequences reported in Table 2 were identified by
Highlighter analysis and confirmed by Hudson-Kaplan, GARD and
Recco analyses.
Mathematical Model
The model employed in the present study has been described
[10,12,34] as have measured parameters of early virus expansion
[52,53,54]. Under this model, with no selection pressure and fast
expansion, one can expect small samples from homogeneous virus
populations to have evolved from a founder strain in a star-like
phylogeny with all sequences coalescing at the founder [10,13].
Occasional deviations from a star phylogeny are, however,
expected. The sampling of 10 sequences, for example, from a
later generation of an exponentially growing population with six-
fold growth per generation (R0=6) has about 3% chance of
including at least one pair sharing the first four generations, a 19%
chance of including sequences that share three, and a 75% chance
of sharing two. Using a point mutation rate of about 1 per 5
generations for the full-length 9 kb HIV-1 genome [10,34], there
is about 75% chance of finding among ten sequences two that
share one mutation, about 20% chance of finding two sequences
that share a pair of mutations, and ,2% chance of sharing more
than that. These probabilities are slightly enhanced by early
stochastic events that can lead to the virus producing less than six
descendants in some generations but are diminished by the
chances that mutations cause a fitness disadvantage that results in
early purifying selection, as previously observed [10,60]. We found
examples of such early stochastic mutations leading to deviations
from star phylogeny in several subjects (Table 2).
Statistical Analyses and Power Calculations
We calculated the statistical significance of differences in rates of
single versus multivariant HIV-1 transmission using Fisher’s exact
test. Differences were considered statistically significant at a value
of p#0.05. To estimate the likelihood of missing infrequently
represented transmitted variants, we described previously a power
study that estimated the probability of sampling low frequency
plasma viral sequences [10]. In a sample set of at least n=20,
there is a 95% probability that a given missed variant comprises
less than 14% of the virus population. For a sample set of 30, there
is a 95% probability not to miss a variant that comprises at least
10% of the total viral population. And for a sample set of 80, there
is a 95% probability not to miss a variant that comprises at least
4% of the total viral population.
We also considered the possibility that the number of
transmitted/founder viruses detected could be influenced by the
clinical stage (Fiebig stage) of the subjects at the time of virus
sampling, because differences in virus replication rates could lead
to increasing differences in virus frequencies with time. If this were
the case and some viruses were outcompeted, the prediction would
be that at later Fiebig stages the numbers of transmitted/founder
virus lineages would be less than at earlier Fiebig stages. Our
model (which is based on previously estimated parameters of an
HIV-1 generation time of 2 days, a reproductive ratio [R0]o f6 ,
and a reverse transcriptase error rate of 2.16610
25 and assumes
that the initial virus replicates exponentially infecting R0 new cells
at each generation and diversifies under a model of evolution that
assumes no selection) predicts that descendants of a transmitted
virus at 45% replicative disadvantage compared to another
transmitted virus, still have more than a 5% chance of occurring
in a sample size of 20, ten generations (,20 days) later. In humans,
the eclipse period, defined as the time between HIV-1 transmis-
sion and first detection of virus in the plasma, has been estimated
to be approximately 10–14 days, and the eclipse period plus Fiebig
stages I and II, approximately 22–26 days [10,33]. In the present
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were 14, 2, 6 and 6, respectively, and this relative distribution was
similar in the three other studies included in the combined analysis
[8,9,10]. As described in the main text, there was no significant
correlation between clinical stage and multiplicity of infection
(Fisher’s exact p=0.53).
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